All Pathways
NephrologyDiagnostic

Glomerulonephritis Evaluation (KDIGO 2021)

Glomerulonephritis Evaluation (KDIGO 2021): Suspected Glomerular Disease → Initial Laboratory Evaluation → Clinical Syndrome Classification → Nephrotic ...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Suspected Glomerular Disease

    Proteinuria, hematuria, or declining kidney function

    1. Action

      Initial Laboratory Evaluation

      Comprehensive workup for suspected GN

      • Urinalysis with microscopy (dysmorphic RBCs, RBC casts)
      • Spot urine protein/creatinine ratio (UPCR)
      • Serum creatinine, eGFR
      • Serum albumin
      • Complete metabolic panel
      • CBC with differential
      1. Decision

        Clinical Syndrome Classification

        Pattern of presentation guides workup

        • Nephrotic: Proteinuria >3.5g/day, hypoalbuminemia, edema, hyperlipidemia
        • Nephritic: Hematuria (RBC casts), HTN, oliguria, modest proteinuria, AKI
        • Mixed: Features of both
        • Asymptomatic: Isolated hematuria or proteinuria
        1. Action

          Nephrotic Syndrome Workup

          Additional testing for nephrotic presentation

          • Anti-PLA2R antibody (membranous nephropathy)
          • Hepatitis B and C serologies
          • HIV
          • ANA (lupus nephritis if positive)
          • Serum and urine protein electrophoresis (SPEP/UPEP)
          • Fasting lipids
          • Consider: Light chains, HbA1c
          1. Action

            Renal Imaging

            Assess kidney size and rule out obstruction

            • Renal ultrasound: Size, echogenicity, obstruction
            • Normal/large kidneys: More likely acute/reversible
            • Small echogenic kidneys: Chronic damage, biopsy may not help
            • Single kidney or other contraindications to biopsy
            1. Decision

              Kidney Biopsy Indicated?

              Consider indications and contraindications

              • Indications:
              • - Unexplained AKI with active sediment
              • - Nephrotic syndrome in adults (except DM >10yr + retinopathy)
              • - Nephritic syndrome with systemic features
              • - Rapidly progressive GN (RPGN)
              • Contraindications: Uncontrolled HTN, bleeding diathesis, single kidney (relative)
              1. Action

                Empiric Management

                If biopsy not performed/pending

                • ACEi/ARB for proteinuria (max tolerated dose)
                • SGLT2i if eGFR allows
                • Blood pressure control <130/80
                • Edema management (diuretics)
                • Statin for hyperlipidemia
                • DVT prophylaxis if severe nephrotic
                1. Outcome

                  Remission/Stable

                  Monitor for relapse, continue nephroprotection

              2. Action

                Proceed with Kidney Biopsy

                Gold standard for GN diagnosis

                • Pre-biopsy: Check BP, coagulation, consent
                • Light microscopy, immunofluorescence, electron microscopy
                • Provides: Diagnosis, activity vs chronicity, prognosis
                • Post-biopsy: Observe 6-24h, check Hgb
                1. Action

                  Interpret Biopsy Results

                  Common diagnoses by pattern

                  • Nephrotic pattern: MCD, FSGS, Membranous, Diabetic
                  • Nephritic pattern: IgAN, Lupus nephritis, ANCA GN, Anti-GBM
                  • MPGN pattern: Consider cryoglobulinemia, C3 glomerulopathy
                  • Activity index guides intensity of treatment
                  • Chronicity index indicates irreversible damage
                  1. Action

                    Disease-Specific Treatment

                    Tailored to biopsy diagnosis

                    • MCD: High-dose steroids (responds well)
                    • FSGS: Steroids, calcineurin inhibitors if refractory
                    • Membranous: Rituximab or CNI if anti-PLA2R+
                    • IgAN: Optimize RAAS blockade, consider steroids if high risk
                    • Lupus nephritis: MMF or cyclophosphamide + steroids
                    • ANCA vasculitis: Rituximab or cyclophosphamide + steroids
                    1. Outcome

                      Refractory/Progressive

                      Consider alternative agents, clinical trial, transplant evaluation

              3. Warning

                RPGN Suspected?

                Rapidly progressive GN is an emergency

                • Features: AKI over days-weeks, active sediment, HTN
                • Causes: ANCA vasculitis, anti-GBM, lupus, PIGN
                • Consider empiric steroids while awaiting biopsy
                • Urgent nephrology consultation
                • May need plasma exchange (anti-GBM, severe ANCA)
        2. Action

          Nephritic Syndrome Workup

          Additional testing for nephritic presentation

          • Complement levels (C3, C4)
          • ANCA (MPO, PR3)
          • Anti-GBM antibody
          • ANA, anti-dsDNA
          • ASO titer (post-streptococcal)
          • Blood cultures if concern for endocarditis
          • Cryoglobulins

Guideline Source

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Kidney biopsy is often required for definitive diagnosis
  • Treatment depends on specific histopathology
  • Does not cover all specific GN subtypes in detail
  • Immunosuppression regimens vary by center

Applicable Regions

EUUSglobal

global: KDIGO 2021 is international guideline; specific treatments may vary

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the Glomerulonephritis Evaluation (KDIGO 2021)?

The Glomerulonephritis Evaluation (KDIGO 2021) is a diagnostic clinical algorithm for Nephrology. It provides a structured decision tree to guide clinical decision-making, based on KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.

What guideline is the Glomerulonephritis Evaluation (KDIGO 2021) based on?

This algorithm is based on KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases (DOI: 10.1016/j.kint.2021.05.021).

What are the limitations of the Glomerulonephritis Evaluation (KDIGO 2021)?

Known limitations include: Kidney biopsy is often required for definitive diagnosis; Treatment depends on specific histopathology; Does not cover all specific GN subtypes in detail; Immunosuppression regimens vary by center. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Glomerulonephritis Evaluation (KDIGO 2021) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free